je.st
news
Home
› Enanta Announces 95 percent SVR12 Rate In AbbVie's Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients
Enanta Announces 95 percent SVR12 Rate In AbbVie's Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients
2015-02-04 07:01:33| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan
Tags: in
rate
study
treatment
Category:Biotechnology and Pharmaceuticals